GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases.
Our lead candidate, uproleselan, is in pivotal Phase 3 development for relapsed / refractory acute myeloid leukemia (AML) and in a Phase 2/3 trial in newly diagnosed AML patients fit for chemotherapy.
Our lead candidate, uproleselan, is in pivotal Phase 3 development for relapsed/refractory AML.
Uproleselan is an investigational first-in-class, E-selectin antagonist.
Uproleselan has received Breakthrough Therapy and Fast Track designations from the U.S. FDA for the treatment of adult AML patients with relapsed or refractory disease.